How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,587 results for

Autoimmune Hemolytic Anemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5. Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. (PubMed)

Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. The physiology of the immune system involves morphologic and functional changes occurring along ageing, with a decrease in immune response and an increase in autoimmune phenomena, even in the absence of overt disese. Autoimmune cytopenias, namely autoimmune hemolytic anemia (AIHA), chronic idiopathic neutropenia (CIN) and aplastic anemia (AA), show different epidemiologic predilection, but are increasingly

2018 European journal of internal medicine

6. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation (PubMed)

Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life

Full Text available with Trip Pro

2018 Blood advances

7. Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab (PubMed)

Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab 30480056 2018 12 07 2341-4545 25 6 2018 Nov GE Portuguese journal of gastroenterology GE Port J Gastroenterol Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab. 340-341 10.1159/000486803 Martins Diana D Gastroenterology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. Ministro Paula P Gastroenterology Department, Centro Hospitalar (...) Tondela-Viseu, Viseu, Portugal. Silva Américo A Gastroenterology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. eng Journal Article 2018 02 14 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Hemolytic anemia Pouchitis Ulcerative colitis Vedolizumab 2017 12 09 2018 01 07 2018 11 28 6 0 2018 11 28 6 0 2018 11 28 6 1 ppublish 30480056 10.1159/000486803 pjg-0025-0340 PMC6243957 N Engl J Med. 2013 Aug 22;369(8):699-710 23964932 Dig Liver Dis. 2017 Apr;49(4):397-404 28063954 Aliment

Full Text available with Trip Pro

2018 GE Portuguese journal of gastroenterology

8. Post-Babesiosis Warm Autoimmune Hemolytic Anemia. (PubMed)

Post-Babesiosis Warm Autoimmune Hemolytic Anemia. Background Babesiosis, a tickborne zoonotic disease caused by intraerythrocytic protozoa of the genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatment and clearance of parasitemia. The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with babesiosis has not previously been well described. Methods After the observation (...) for clinical hemolysis was found. WAHA required immunosuppressive treatment in 4 of the 6 patients. Conclusions We documented post-babesiosis WAHA in patients who did not have a history of autoimmunity; asplenic patients appeared to be particularly at risk.

2017 NEJM

9. Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors. (PubMed)

Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors. Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed

2019 American journal of hematology

10. Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. (PubMed)

Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. Infectious mononucleosis is one of the main manifestations of Epstein - Barr virus, which is characterized by fever, tonsillar-pharyngitis, lymphadenopathy and atypical lymphocytes. Although 60% of patients with IMN develop cold type antibodies, clinically significant hemolytic anemia with a high ferritin level is very rare and validity of serum ferritin (...) any intervention following two weeks of the acute infection.Cold type autoimmune hemolytic anemia is a rare manifestation of infectious mononucleosis and serum ferritin is used very rarely as an important biomarker. Management of cold type anemia is mainly supportive and elevated serum ferritin indicates severe viral disease.

Full Text available with Trip Pro

2019 BMC Infectious Diseases

11. A case of pernicious anemia requiring differential diagnosis of autoimmune hemolytic anemia complication (PubMed)

A case of pernicious anemia requiring differential diagnosis of autoimmune hemolytic anemia complication An 80-year-old female was admitted to our hospital due to malaise. The initial diagnosis on admission was pernicious anemia (PA), Hashimoto thyroiditis and autoimmune atrophic gastritis. Autoimmune hemolytic anemia was suspected because direct antiglobulin test (DAT) was positive. Treatment with vitamin B12 improved anemia, with the disappearance of hemolysis. In some cases, PA patients (...) with positive DAT may have hemolysis without the involvement of the autoimmune mechanism. Therefore, it is important to carefully assess PA patients with hemolysis and positive DAT for the prevention of unnecessary administration of steroid therapy.

Full Text available with Trip Pro

2017 Oxford Medical Case Reports

12. Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature (PubMed)

Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-retated disease that is often associated with IgG4-related sclerosing cholangitis (IgG4-SC). Autoimmune hemolytic anemia (AIHA) is an immune-related disease that causes hemolytic anemia. Although type 1 AIP/IgG4-SC (...) and AIHA have a shared etiology as a presumed autoimmune disease, they rarely overlap, and their association has not been clarified. Secondary AIHA might not be diagnosed appropriately because the obstructive jaundice observed in type 1 AIP/IgG4-SC can obscure the presence of hemolytic jaundice. We herein report a case of type 1 AIP/IgG4-SC overlapping with secondary AIHA along with a review of the literature.

Full Text available with Trip Pro

2017 Internal Medicine

13. Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. (PubMed)

Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies to red blood cells (RBCs), which can be panreactive and/or specific to Rh/other blood group antigens. We report a severe case of AIHA after bone marrow transplantation (BMT) due to autoanti-D triggered by reactivation of Epstein-Barr virus (EBV

2018 Transfusion

14. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Españo (PubMed)

Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Españo Autoimmune hemolytic anemia (AIHA) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) associated with poor outcome. However, an optimal therapeutic approach is lacking. Between 2000 and 2015, 4099 allogeneic HSCT

2018 Transfusion medicine reviews

15. Rosai-Dorfman Disease Complicated by Autoimmune Hemolytic Anemia in a Child: A Case Report and Review of the Literature (PubMed)

Rosai-Dorfman Disease Complicated by Autoimmune Hemolytic Anemia in a Child: A Case Report and Review of the Literature Rosai-Dorfman disease is a rare histiocytic proliferative disorder that commonly presents with a massive lymphadenopathy and a variety of constitutional symptoms. Severe hemolytic anemia is an infrequent complication of this disease. Although the etiology of the condition is unknown, infectious agents including viruses have been implicated. We describe a 2-year-old female (...) child who presented with fever, pallor, and generalized lymphadenopathy complicated by the development of autoimmune hemolytic anemia. A review of the literature of this condition is also provided.

Full Text available with Trip Pro

2018 Case reports in oncology

16. A Unique Triad: Ulcerative Colitis, Primary Sclerosing Cholangitis, and Autoimmune Hemolytic Anemia (PubMed)

A Unique Triad: Ulcerative Colitis, Primary Sclerosing Cholangitis, and Autoimmune Hemolytic Anemia Ulcerative colitis is an autoimmune disorder leading to chronic intestinal inflammation. It can present with a wide range of associated extra-intestinal manifestations. We present a case of an 18-year-old man diagnosed with ulcerative colitis, autoimmune hemolytic anemia and primary sclerosing cholangitis during the same hospitalization. The unique triad of these diseases gives important clues

Full Text available with Trip Pro

2018 Cureus

17. Bartonella endocarditis in a child with tetralogy of Fallot complicated by PR3‐ANCA positive serology, autoimmune hemolytic anemia, and acute kidney injury (PubMed)

Bartonella endocarditis in a child with tetralogy of Fallot complicated by PR3‐ANCA positive serology, autoimmune hemolytic anemia, and acute kidney injury Although the role of ANCA in infective endocarditis is unclear, Bartonella henselae has been implicated as the culprit in cases of PR3-ANCA positive subacute bacterial endocarditis (SBE) with glomerulonephritis. In this case, a Coombs-positive autoimmune hemolytic anemia and glomerulonephritis accompanied a PR3-ANCA positive SBE caused

Full Text available with Trip Pro

2018 Clinical Case Reports

18. Current treatment options for severe autoimmune hemolytic anemia (PubMed)

Current treatment options for severe autoimmune hemolytic anemia 30116136 2018 11 14 1306-0015 53 2 2018 Jun Turk pediatri arsivi Turk Pediatri Ars Current treatment options for severe autoimmune hemolytic anemia. 129-130 10.5152/TurkPediatriArs.2018.6499 Yeşilbaş Osman O Unit of Pediatric Intensive Care, Health Sciences University, Van Training and Research Hospital, Van, Turkey. eng Journal Article Comment 2018 06 01 Turkey Turk Pediatri Ars 9803140 Turk Pediatri Ars. 2017 Sep 1;52(3):169-172

Full Text available with Trip Pro

2018 Turkish Archives of Pediatrics/Türk Pediatri Arşivi

19. Re: Current treatment options for severe autoimmune hemolytic anemia (PubMed)

Re: Current treatment options for severe autoimmune hemolytic anemia 30116137 2018 11 14 1306-0015 53 2 2018 Jun Turk pediatri arsivi Turk Pediatri Ars Re: Current treatment options for severe autoimmune hemolytic anemia. 130-131 10.5152/TurkPediatriArs.2018.2121 Özdemir Zeynep Canan ZC Department of Pediatrics, Division of Pediatric Hematology and Oncology, Eskişehir Osmangazi University School of Medicine, Eskişehir, Turkey. Department of Pediatrics, Pediatric Intensive Care and Infectious

Full Text available with Trip Pro

2018 Turkish Archives of Pediatrics/Türk Pediatri Arşivi

20. A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia A Study of Parsaclisib in Participants With Autoimmune Hemolytic Anemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study (...) of Parsaclisib in Participants With Autoimmune Hemolytic Anemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03538041 Recruitment Status : Recruiting First Posted : May 25, 2018 Last Update Posted : March 21, 2019 See Sponsor

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>